Merrill Lynch Resumes Coverage on Gilead Sciences (GILD)
More News related to GILD
- Gilead Sciences to Present at Two Upcoming Investor Conferences
- Gilead Sciences Announces Notification of ANDA Filing for Truvada
- David Moenning's Daily State of the Markets: 11/12
- Notable Analyst Rating Changes 11/12: BBBY, PAG, ROK Upgraded; EGLE, FMCN, BRCM Downgraded
- Needham & Co Initiates Coverage on Gilead Sciences (GILD), Represents Core Holding
More News related to New Coverage
- B. Riley Downgrades Doral Financial (DRL) to Neutral
- CL King Downgrades Ceragon (CRNT) to Accumulate
- Matrix Upgrades/Downgrades for December 1, 2008
- Raymond James Downgrades Allscripts (MDRX) to Market Perform
- RBC Capital Downgrades Strategic Hotels & Resorts (BEE) to Underperform
Merrill Lynch resumes coverage on Gilead Sciences (Nasdaq: GILD) with a Neutral.
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need.
Related Categories
New CoverageStocks Mentioned
-2.33Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
